RCUS
Arcus Biosciences, Inc.
RCUS trails on the overall score without a compensating advantage in the available component scores.
UNH
UnitedHealth Group Incorporated
UNH has the edge over RCUS overall, supported by stronger fundamentals and lower modeled downside.
RCUS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Strong |
RCUS's balance sheet is currently strong, but its revenue, profitability and cash flow are weak.
UNH Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Healthy |
UNH's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
RCUS PE Valuation
RCUS has no meaningful PE right now: it lost money over the past year.
UNH PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 18x | $405 | — |
| Cheap | 19x | $325 | -20% |
| Fair | 23x | $410 | +1.2% |
| Current | 23x | $405 | — |
| Expensive | 30x | $526 | +30% |
Historical ranges are pointers, not guarantees.
UNH's PE is in its fair range at 23x. If earnings grow as analysts expect, today's price would be 18x next year's earnings, in its cheap range.
RCUS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect RCUS's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
UNH Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Stable | |
| Improving | |
| Moderate | |
| Low |
Analysts expect UNH's earnings to grow and its profitability to improve, with its revenue holding steady. However, they disagree widely on these estimates.
RCUS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$3.62 | -$0.18 |
| Q2 2026 | -$3.89 | -$0.72 |
| Q1 2026 | -$3.17 | +$1.02 |
| Q4 2025 | -$3.29 | -$0.19 |
| Q3 2025 | -$3.44 | -$0.29 |
| Q2 2025 | -$3.17 | -$0.08 |
| Q1 2025 | -$4.19 | -$1.08 |
| Q4 2024 | -$3.10 | +$1.05 |
RCUS lost $3.62 per share over the past year, about the same as its loss the year before.
UNH Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.65 | +29% |
| Q3 2026 | $17.55 | -8.5% |
| Q2 2026 | $15.58 | -33% |
| Q1 2026 | $13.28 | -44% |
| Q4 2025 | $13.23 | -15% |
| Q3 2025 | $19.17 | +25% |
| Q2 2025 | $23.09 | +53% |
| Q1 2025 | $23.89 | +46% |
| Q4 2024 | $15.51 | -35% |
UNH has the edge over RCUS on earnings quality, reporting a profit while its opponent remains loss making.
RCUS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9M | -65% |
| Q2 2026 | $41M | -74% |
| Q1 2026 | $17M | -39% |
| Q4 2025 | $33M | +27% |
| Q3 2025 | $26M | -46% |
| Q2 2025 | $160M | +310% |
| Q1 2025 | $28M | -81% |
| Q4 2024 | $26M | -16% |
RCUS's revenue has slid since its 2021 peak: $9M last quarter, down 65% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1456% | -909 points |
| Q2 2026 | -234% | -229 points |
| Q1 2026 | -788% | -353 points |
| Q4 2025 | -345% | +51 points |
| Q3 2025 | -546% | -327 points |
| Q2 2025 | -5% | +267 points |
| Q1 2025 | -436% | -425 points |
| Q4 2024 | -396% | -103 points |
RCUS's operating margin was −1456% last quarter, down 909 points from the same quarter a year ago, near the bottom of its range since 2019.
UNH Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $112.7B | -0.4% |
| Q2 2026 | $112B | +0.4% |
| Q1 2026 | $111.7B | +2% |
| Q4 2025 | $113.2B | +12% |
| Q3 2025 | $113.2B | +12% |
| Q2 2025 | $111.6B | +13% |
| Q1 2025 | $109.6B | +9.8% |
| Q4 2024 | $100.8B | +6.8% |
UNH has the edge over RCUS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +2 points |
| Q2 2026 | 7.1% | +2.5 points |
| Q1 2026 | 8.1% | -0.3 points |
| Q4 2025 | 0.3% | -7.4 points |
| Q3 2025 | 3.8% | -4.8 points |
| Q2 2025 | 4.6% | -3.4 points |
| Q1 2025 | 8.3% | +0.4 points |
| Q4 2024 | 7.7% | -0.4 points |
UNH has the edge over RCUS on profitability, with a higher operating margin.
RCUS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$88M | +$9M |
| Q2 2026 | -$119M | +$14M |
| Q1 2026 | -$138M | -$5M |
| Q4 2025 | -$121M | -$20M |
| Q3 2025 | -$97M | -488% |
| Q2 2025 | -$133M | -$39M |
| Q1 2025 | -$133M | -$127M |
| Q4 2024 | -$101M | -$7M |
RCUS has burned cash in almost every quarter: −$466M over the past year, against −$464M the year before.
UNH Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $4.3B | -16% |
| Q2 2026 | $10.3B | +63% |
| Q1 2026 | $8.1B | +79% |
| Q4 2025 | $160M | -89% |
| Q3 2025 | $5.1B | -61% |
| Q2 2025 | $6.3B | +6.9% |
| Q1 2025 | $4.6B | +1037% |
| Q4 2024 | $1.5B | +$7.6B |
UNH has the edge over RCUS on cash generation, producing positive trailing cash flow while its opponent burns cash.
RCUS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1% | +1.3M shares |
| 1 year | +20% | +20.9M shares |
| 3 years | +71% | +52.8M shares |
| 5 years | +82% | +57.3M shares |
| Available history | +189% | +83.3M shares |
RCUS has 127M diluted shares, up 20% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
UNH Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -4M shares |
| 1 year | -0.7% | -6M shares |
| 3 years | -3.6% | -34M shares |
| 5 years | -5.5% | -53M shares |
| Available history | -6.6% | -64M shares |
UNH has the edge over RCUS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $3.4B |
| Q2 2026 | $1.6B |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $2.5B |
| Q1 2025 | $3B |
| Q4 2024 | $5B |
UNH spent $5B buying back its own shares over the past year, down 52% from the year before.
RCUS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2022 | -2.7x | Net Cash |
| Q2 2022 | -3.8x | Net Cash |
| Q1 2022 | -8.5x | Net Cash |
| Q4 2021 | -2.6x | Net Cash |
RCUS has more cash than debt.
UNH Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.7x | Healthy |
| Q2 2026 | 1.7x | Healthy |
| Q1 2026 | 2.2x | Moderate |
| Q4 2025 | 2.3x | Moderate |
| Q3 2025 | 1.7x | Healthy |
| Q2 2025 | 1.5x | Healthy |
| Q1 2025 | 1.3x | Healthy |
| Q4 2024 | 1.4x | Healthy |
UNH's net debt is about 1.7 years of its operating earnings (EBITDA), about the same as a year ago.
RCUS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.2 | Neutral |
| Stochastic | 4.6 | Oversold |
RCUS's weekly RSI is 31 (neutral) and its Stochastic is 5 (oversold).
UNH Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 56.4 | Neutral |
| Stochastic | 60.0 | Neutral |
UNH's weekly RSI is 56 (neutral) and its Stochastic is 60 (neutral).
RCUS PE vs Healthcare Sector
| Metric | RCUS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
RCUS has no meaningful PE right now: it lost money over the past year.
UNH PE vs Healthcare Sector
| Metric | UNH | Sector median | Relative |
|---|---|---|---|
| PE | 23x | 26x | 11% below |
| PE % | 47 | 29 | 18 pts above |
UNH is trading at 23x earnings, a 11% discount to the Healthcare sector's median of 26x.
RCUS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $21.1 | 16% below |
| 20 week MA | $25.5 | 30% below |
| 50 week MA | $23.9 | 26% below |
| 100 week MA | $18.0 | 1.1% below |
| 200 week MA | $17.8 | 0.1% above |
RCUS has fallen below most of its moving averages, though it's still 0.1% above its 200-week average.
UNH Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $394.2 | 2.8% above |
| 20 week MA | $400.5 | 1.2% above |
| 50 week MA | $361.2 | 12% above |
| 100 week MA | $376.0 | 7.8% above |
| 200 week MA | $446.6 | 9.3% below |
UNH has the edge over RCUS on trend strength, trading above more of its moving averages.
RCUS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.7 | $30.6 | +187% |
| 2021 | $30.6 | $44.6 | +46% |
| 2022 | $44.6 | $20.4 | -54% |
| 2023 | $20.4 | $19.1 | -6.4% |
| 2024 | $19.1 | $15.3 | -20% |
| 2025 | $15.3 | $23.1 | +51% |
| 2026 YTD | $23.1 | $17.8 | -23% |
RCUS's yearly returns have swung widely, from +187% in 2020 to −54% in 2022. It's down 23% so far in 2026.
UNH Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $296.0 | $340.8 | +15% |
| 2021 | $340.8 | $495.4 | +45% |
| 2022 | $495.4 | $531.3 | +7.3% |
| 2023 | $531.3 | $526.5 | -0.9% |
| 2024 | $526.5 | $510.0 | -3.1% |
| 2025 | $510.0 | $331.8 | -35% |
| 2026 YTD | $331.8 | $405.1 | +22% |
UNH has the edge over RCUS on returns for 2026, with the stronger performance.